Allergan says no to $53B as Valeant gets hostile

Allergan CEO David Pyott

Allergan's ($AGN) board has unanimously shrugged off the latest bid from Valeant Pharmaceuticals ($VRX) and activist investor Bill Ackman, dismissing a $53 billion offer and setting the stage for a proxy fight. Valeant's latest proposal, under which each shareholder would get $72 and 0.83 shares of Valeant per Allergan share, "substantially undervalues" the company, CEO David Pyott said in a statement, and Allergan is sticking to its assertion that a Valeant takeover would hamstring its growth. The parties have never formally discussed a buyout, and that's not about to change, Pyott said. Instead, Valeant and Ackman's Pershing Square Capital Management, which owns 9.7% of Allergan, are taking their pitch to shareholders, seeking a special meeting to depose 6 members of the company's board to get the deal done. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.